6 completed. 3 Phase 3, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow ethylmethylhydroxypyridine succinate: new trials by email Literature Review of ethylmethylhydroxypyridine succinate trials Research Report on ethylmethylhydroxypyridine succinate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) Mexidol - Primary Open-Angle Glaucoma (POAG) | Phase 4 | Completed | Pharmasoft | 80 | 2023-09-15 | 2025-12-12 |
| MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure Mexidol - Ischemic Stroke, Acute | Phase 4 | Completed | Pharmasoft | 60 | 2023-04-17 | 2025-04-27 |
| Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) Mexidol, Placebo - Primary Open-Angle Glaucoma (POAG) | Phase 2 | Completed | Pharmasoft | 102 | 2021-11-15 | 2025-12-12 |
| Efficacy and Safety of Mexidol® in Stroke Therapy Mexidol (Ethylmethylhydroxypyridine Succinate), Placebo - Ischemic Stroke | Phase 3 | Completed | Pharmasoft | 304 | 2019-11-18 | 2025-12-30 |
| Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia Mexidol, Placebo - Chronic Cerebral Ischemia | Phase 3 | Completed | Pharmasoft | 318 | 2019-11-05 | 2025-10-06 |
| Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy Mexidol, Placebo - Ischemic Stroke | Phase 3 | Completed | Pharmasoft | 150 | 2015-03-06 | 2025-02-24 |
Stroke (4) · Ischemic Stroke (3) · Brain Ischemia (2) · Glaucoma (2) · Glaucoma, Open-Angle (2) · Mitochondrial Diseases (2) · Brain Injuries, Traumatic (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Cognitive Dysfunction (1) · Hypoxia, Brain (1) · Ischemia (1) · Neurobehavioral Manifestations (1)
Pharmasoft (6)
Russia (6) · Uzbekistan (2) · Kazakhstan (1)
Aida A. Yakupova, MD, Cand.Med.Sci (1) · Aleksandr Y. Malygin, MD, Dr.Med.Sci (1) · Alina S. Agafina, MD, Cand.Med.Sci (1) · Andrey M. Alasheev, MD, Dr.Med.Sci (1) · Elena V. Vostrikova, MD, Cand.Med.Sci (1) · Galina A. Batishcheva, Prof., Dr.Med.Sci (1) · Igor V. Litvinenko, Prof., Dr.Med.Sci (1) · Irina G. Lukashevich, MD (1) · Larisa A. Shchepankevich, MD, Dr.Med.Sci (1) · Marine M. Tanashyan, Prof., Dr.Med.Sci (1) · Min G. Omelyanenko, MD, Dr.Med.Sci (1) · Olga A. Sinitsyna, MD, Cand.Med.Sci (1) · Olga D. Ostroumova, Prof., Dr.Med.Sci (1) · Stanislav O. Pozdnyakov, MD, Cand.Med.Sci (1) · Yokutkhon N. Madzhidova, Prof., Dr.Med.Sci (1)